Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
20 Dec 2018 at 12:00 pm ETPDF Version
BASEL, Switzerland, Dec. 20, 2018 /PRNewswire/ — Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women’s health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will begin at 9:00 a.m. PT on Tuesday, January 8, 2019 at the Westin St. Francis, followed by a Q&A session at 9:30 a.m. PT.
The company’s presentation will be webcast live and will be accessible from the Events page under the Investors and Media section of the Myovant website at www.myovant.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.
About Myovant Sciences
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women’s health and endocrine diseases. Myovant’s lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist. Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO). Myovant is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that is in Phase 2a development for the treatment of female infertility as part of assisted reproduction. Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Over time, Myovant intends to expand its development pipeline to include other potential treatments for women’s health and endocrine diseases. For more information, please visit Myovant’s website at www.myovant.com.
Chief Financial Officer
Myovant Sciences, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/myovant-sciences-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-300769409.html
SOURCE Myovant Sciences